IMRX

Immuneering Corporation Class A (IMRX)

About Immuneering Corporation Class A (IMRX)

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Details

Daily high
$2.26
Daily low
$2.12
Price at open
$2.22
52 Week High
$8.89
52 Week Low
$1.00
Market cap
64.9M
Dividend yield
0.00%
Volume
103
Avg. volume
8.0M
P/E ratio
-1.15

Immuneering Corporation Class A News

Details

Daily high
$2.26
Daily low
$2.12
Price at open
$2.22
52 Week High
$8.89
52 Week Low
$1.00
Market cap
64.9M
Dividend yield
0.00%
Volume
103
Avg. volume
8.0M
P/E ratio
-1.15